Argent BioPharma Limited (ASX:RGT)

Market Cap	8.66M
Revenue (ttm)	295.83K
Net Income (ttm)	-22.62M
Shares Out	72.18M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,157
Average Volume	32,593
Open	0.1250
Previous Close	0.1200
Day's Range	0.1200 - 0.1250
52-Week Range	0.1100 - 0.5700
Beta	0.50
RSI	42.26
Earnings Date	May 29, 2025

About Argent BioPharma

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the tr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RGT

Financial Performance

In 2024, Argent BioPharma's revenue was 891,083, a decrease of -73.70% compared to the previous year's 3.39 million. Losses were -17.53 million, -15.81% less than in 2023.